Haemophilus influenzae type b conjugate vaccines: Update

S. A. Plotkin, R. S. Daum, G. S. Giebink, C. B. Hall, M. L. Lepow, E. K. Marcuse, G. H. McCracken, C. F. Phillips, G. B. Scott, H. T. Wright

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


On December 22, 1988, a second conjugate vaccine was licensed by the US Food and Drug Administration for the prevention of infections caused by H influenzae type b in children 18 months of age or older. This newly licensed vaccine is a conjugate of H influenzae type b capsular oligosaccharide and a nontoxic mutant diphtheria toxin protein molecule called CRM197. The official designation of this vaccine is 'Haemophilus b conjugate vaccine (diphtheria CRM197 protein conjugate)' and it is often referred to as HbOC.

Original languageEnglish (US)
Pages (from-to)386-387
Number of pages2
Issue number2
StatePublished - 1989

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Haemophilus influenzae type b conjugate vaccines: Update'. Together they form a unique fingerprint.

Cite this